Valuation: Adocia

Market Cap 81.12M 93.92M 76.23M 69.33M 130M 8.98B 132M 893M 349M 4.5B 353M 345M 14.95B P/E 2026 *
-757x
P/E 2027 * 5.99x
Enterprise Value 51.28M 59.37M 48.18M 43.82M 82.39M 5.68B 83.74M 565M 221M 2.84B 223M 218M 9.45B EV / Sales 2026 *
20.3x
EV / Sales 2027 * 3.14x
Free-Float
95.03%
Yield 2026 *
-
Yield 2027 * -
1 day-14.23%
1 week+18.00%
Current month+21.64%
1 month+24.74%
3 months-4.31%
6 months-26.36%
Current year-25.80%
1 week 4.1
Extreme 4.1
4.89
1 month 3.72
Extreme 3.716
4.89
Current year 3.69
Extreme 3.69
7.45
1 year 3.69
Extreme 3.69
12.24
3 years 3.15
Extreme 3.15
16.16
5 years 2.8
Extreme 2.79668
16.16
10 years 2.8
Extreme 2.79668
61.28
Manager TitleAgeSince
Chief Executive Officer 55 11/05/2023
Director of Finance/CFO - 23/09/2024
Chief Tech/Sci/R&D Officer - 01/12/2014
Director TitleAgeSince
Director/Board Member 55 19/04/2013
Chairman 80 24/02/2012
Director/Board Member 58 18/06/2013
Change 5-day change 1-year change 3-year change Capi.($)
-14.42%+18.00% - - 93.92M
-1.90%+2.85%+62.82%+104.39% 70.07B
+12.46%+7.07%+43.22%+79.85% 52.87B
-2.05%-5.61%-3.18%+449.22% 27.02B
+2.26%+0.09%+48.90%+11.90% 23.61B
+1.05%-0.62%-18.00%-13.77% 23.38B
+3.81%+20.97%+266.37%+477.93% 19.43B
+2.91%+5.12%+38.91%-15.67% 18.75B
+0.38%-1.14%+16.94%+567.31% 15.85B
+1.24%-5.23%+33.75%+140.34% 12.7B
Average +0.56%-0.89%+54.42%+200.17% 29.3B
Weighted average by Cap. +2.61%-1.40%+52.85%+164.60%

Financials

2026 *2027 *
Net sales 2.52M 2.92M 2.37M 2.15M 4.05M 279M 4.12M 27.76M 10.85M 140M 10.96M 10.72M 465M 35.4M 40.99M 33.27M 30.25M 56.88M 3.92B 57.82M 390M 152M 1.96B 154M 151M 6.52B
Net income -4.32M -5M -4.06M -3.69M -6.94M -478M -7.05M -47.53M -18.58M -239M -18.77M -18.36M -795M -44.33M -51.32M -41.65M -37.88M -71.22M -4.91B -72.4M -488M -191M -2.46B -193M -189M -8.17B
Net Debt -29.84M -34.55M -28.04M -25.5M -47.95M -3.3B -48.74M -329M -128M -1.65B -130M -127M -5.5B 30.18M 34.94M 28.36M 25.79M 48.48M 3.34B 49.28M 332M 130M 1.67B 131M 128M 5.56B
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
73
Date Price Change Volume
15/05/25 EUR 4.890 -8.86% 2,399
14/08/26 EUR 4.160 -0.95% 21
13/08/26 EUR 4.200 +1.45% 1,250
11/08/26 EUR 4.140 +1.17% 21
10/08/26 EUR 4.092 -1.25% 506
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.146EUR
Average target price
9.700EUR
Spread / Average Target
+133.96%

Quarterly revenue - Rate of surprise